Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MEDX ... anybody following? -- Ignore unavailable to you. Want to Upgrade?

To: Icebrg who wrote (663)	4/24/2003 1:29:39 PM
From: nigel bates	Respond to of 2240

COPENHAGEN, Denmark, April 24 /PRNewswire-FirstCall/ -- Genmab A/S (CSE: GEN - News) held its Annual General Meeting on April 24, 2003 at 2:00 p.m. at the Radisson SAS Scandinavia Hotel, Amager Boulevard 70, 2300 Copenhagen S, Denmark. At the meeting resigning Chairman of the Board Jesper Zeuthen gave -- on behalf of the Board -- a report on Genmab's activities during the year. Chief Executive Officer and member of the Board, Lisa N. Drakeman presented the Annual Report for 2002 endorsed by the auditors. The Report was approved and discharge was given to the Board and the Management. It was decided that the year's loss of DKK 479 million be carried forward by transfer to accumulated deficit, as stated in the Annual Report. Jesper Zeuthen resigned as member of the Board. Ernst Schweizer and Irwin Lerner were re-elected as board members, both for a period expiring at the Annual General Meeting held in 2006. In accordance with Article 13 of the articles of association, the board members Michael Widmer, Karsten Havkrog Pedersen and Lisa N. Drakeman were not up for election. Details on Ernst Schweizer and Irwin Lerner can be found on www.genmab.com. PricewaterhouseCoopers (state authorized accountants) and Deloitte & Touche (state authorized accountants) were re-elected as auditors of the Company. The General Meeting adopted all proposals from the Board to change the Company's articles of association, as follows: Proposal to change the articles of association (new article 6A) so that the Board is authorised to issue warrants to subscribe the Company's shares up to a nominal value of DKK 500,000 divided into shares of DKK 1 to members of the Company's Board of Directors, the Company's employees and consultants as well as employees and consultants of the Company's subsidiaries it being noted, however, that the Board of Directors is prohibited from issuing warrants to members of the Board of Directors and registered managers to whom warrants previously have been issued. At the same time the Board of Directors is authorised for a period expiring on April 23, 2008 to increase the nominal registered share capital of the Company on one or more times up to the nominal value of DKK 500,000 through cash payments in connection with the exercise of warrants. Proposal to change Article 9, 4th paragraph, first sentence, regarding the calling of general meetings so that forthwith general meetings shall be called by the Board by advertisement inserted in no less than one Danish nation-wide newspaper (previously callings should also be inserted in the Danish Official Gazette and one European-wide newspaper). Proposal to change Article 7, second sentence, so that the register of shareholders shall be kept by Danske Bank A/S (previously Carnegie Bank A/S). Proposal to change Articles 9, 10 and 13 as a consequence of changes in the Danish Financial Statements Act and in the Danish Companies Act to the effect that forthwith Ordinary General Meetings shall be held no later than 4 months after the end of the financial year (previously 5 months after the end of the financial year), that the phrase "Annual Accounts" be changed to "Annual Report" and that the phrase "loss" be changed to "deficit". A proposal from a shareholder, that the Board may only receive share options if it has been included as a separate item on the agenda for the Annual General Meeting was not adopted by the General Meeting during a written vote. After the meeting the Board convened and constituted itself with Michael Widmer as Chairman... Shame...

To: Icebrg who wrote (663)	5/15/2003 2:13:58 AM
From: Icebrg	Read Replies (1) \| Respond to of 2240

Medarex and Amrad Agreement (May 15, 2003) NEWS RELEASE MEDAREX AND AMRAD ANNOUNCE AGREEMENT TO DEVELOP THERAPEUTIC ANTIBODIES Princeton, N.J. and Victoria, Australia; May 15, 2003 – Medarex, Inc. (Nasdaq:MEDX) and Amrad Corporation Limited (ASX:AML) today announced a licensing partnership for the research and development of fully human therapeutic antibodies against interleukin-13 receptor alpha, a target in which Amrad has a proprietary interest. Amrad is using Medarex’s UltiMAb Human Antibody Development SystemSM to generate antibodies to this target. Medarex expects to receive license fees and milestone payments, as well as royalties on commercial sales of any products that may result from this agreement. “The development of antagonists to the interleukin-13 receptor for the treatment of asthma is one of our priority projects,” said Dr. Sandra Webb, Managing Director and CEO of Amrad. “The receptor was discovered through our collaboration with the Cooperative Research Centre for Cellular Growth Factors (CRC-CGF), and Amrad continues to work with Medarex to generate antibodies to the receptor. We are pleased to secure our ongoing access to Medarex’s human antibody technology for use in this exciting project.” “We believe that Amrad is a leader in the Australian biotech community with a multi-product pipeline and links to many of Australia’s biomedical institutes,” said Donald L. Drakeman, President and CEO of Medarex. “We hope to see UltiMAb antibodies moving forward soon in Amrad’s programs.” About Amrad Amrad Corporation Limited is an Australian drug discovery and development based biotechnology company. Amrad's in-house R&D expertise is focused on five flagship status projects in the areas of allergy and inflammation, anti-infectives and neurological indications. Further information about projects in drug discovery and development can be found at www.amrad.com.au.